Ardelyx, Inc. (ARDX)
Market Cap | 1.14B |
Revenue (ttm) | 251.85M |
Net Income (ttm) | -72.58M |
Shares Out | 236.85M |
EPS (ttm) | -0.32 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 4,926,849 |
Open | 4.630 |
Previous Close | 4.690 |
Day's Range | 4.580 - 4.960 |
52-Week Range | 4.320 - 10.130 |
Beta | 0.83 |
Analysts | Buy |
Price Target | 11.75 (+143.78%) |
Earnings Date | Oct 31, 2024 |
About ARDX
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of el... [Read more]
Financial Performance
In 2023, Ardelyx's revenue was $124.46 million, an increase of 138.61% compared to the previous year's $52.16 million. Losses were -$66.07 million, -1.70% less than in 2022.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for ARDX stock is "Buy." The 12-month stock price forecast is $11.75, which is an increase of 143.78% from the latest price.
News
Ardelyx Lost The Lawsuit, But The Kidney PATIENT Act Will Save It
Ardelyx lost a lawsuit against Medicare, impacting XPHOZAH's revenue potential, with no other major prospects in its pipeline. CMS's decision to move XPHOZAH to the bundled payment system significantl...
Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference
WALTHAM, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med...
Ardelyx's Medicare Setback Casts Doubt On Long-Term Viability
Ardelyx's Q3 revenue grew to $98 million, with strong Xphozah sales despite CMS's recent bundling ruling impacting future reimbursement. The CMS lawsuit dismissal affected Xphozah's reimbursement pros...
Ardelyx Responds to District Court Decision Granting Motion to Dismiss
Inclusion of oral-only phosphate-lowering therapies in the ESRD PPS will put dialysis patients' health at risk Inclusion of oral-only phosphate-lowering therapies in the ESRD PPS will put dialysis pat...
Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference
WALTHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med...
Ardelyx, Inc. (ARDX) Q3 2024 Earnings Call Transcript
Ardelyx, Inc. (NASDAQ:ARDX) Q3 2024 Earnings Conference Call October 31, 2024 4:30 PM ET Company Participants Caitlin Lowie - Vice President of Corporate Communications & Investor Relations Michael R...
Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update
IBSRELA generates $40.6 million in net product sales revenue; Company expects full year 2024 IBSRELA net sales revenue to be between $145 and $150 million
Ardelyx Presents Results from its IBS in America 2024 Supplemental Survey at the American College of Gastroenterology's (ACG) Annual Meeting
Ninety percent of survey participants reported “some” or “significant” negative impact of IBS-C on their life Survey results presented in two poster presentations WALTHAM, Mass., Oct. 28, 2024 (GLOBE ...
Ardelyx Announces Launch of Gut Matters: Discoveries and Innovations, a New Podcast for the IBS-C Patient Community
WALTHAM, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med...
Ardelyx to Report Third Quarter 2024 Financial Results on October 31, 2024
WALTHAM, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med...
Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the American Society of Nephrology's Kidney Week
WALTHAM, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med...
The Schall Law Firm Encourages Shareholder Participation In A Securities Fraud Case Against Ardelyx, Inc.
LOS ANGELES, CA / ACCESSWIRE / October 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a category motion lawsuit against Ardelyx, Inc. ("Ardelyx" or...
Shareholders of Ardelyx, Inc. Should Contact The Gross Law Firm Before October 15, 2024 to Discuss Your Rights - ARDX
NEW YORK , Oct. 14, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Ardelyx, Inc. (NASDAQ: ARDX). Shareholders who purchased shares of ARDX during the class peri...
Ardelyx Inc Is Being Sued For Violating Securities Laws And Affected Investors Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / October 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a category motion lawsuit against Ardelyx, Inc. ("Ardelyx" or...
Rosen Law Firm Urges Ardelyx, Inc. (NASDAQ: ARDX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers and acquirers of securities of Ardelyx, Inc....
Ardelyx, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CXM
LOS ANGELES , Oct. 11, 2024 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Ardelyx, Inc. ("Ardelyx" or "the Company") (NASDAQ: ARDX) for violations of §§10(b) an...
Ardelyx Inc Is Being Sued For Violating Securities Laws And Affected Investors Are Urged To Reach Out To The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / October 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a category motion lawsuit against Ardelyx, Inc. ("Ardelyx" or ...
Ardelyx Announces Publication of a Review Article Exploring the Patient Burden and Therapeutic Landscape of IBS-C in the U.S. in Clinical and Experimental Gastroenterology
WALTHAM, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med...
Ardelyx, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. October 15, 2024 Deadline to file Lead Plaintiff Motion.
Investors can contact the law firm at no cost to learn more about recovering their losses
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 15, 2024 in Ardelyx, Inc. Lawsuit – ARDX
NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Ardelyx, Inc. (NASDAQ: ARDX).
Ardelyx Inc Is Being Sued For Violating Securities Laws And Impacted Investors Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / October 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a category motion lawsuit against Ardelyx, Inc. ("Ardelyx" or ...
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Ardelyx To Contact Him Directly To Discuss Their Options NEW YORK...
The Schall Law Firm Invites Stockholder Participation In A Securities Fraud Case Against Ardelyx, Inc.
LOS ANGELES, CA / ACCESSWIRE / September 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a category motion lawsuit against Ardelyx, Inc. ("Ardelyx" ...
The Schall Law Firm Invites Shareholder Participation In A Securities Fraud Case Against Ardelyx, Inc.
LOS ANGELES, CA / ACCESSWIRE / September 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a category motion lawsuit against Ardelyx, Inc. ("Ardelyx" ...
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Ardelyx To Contact Him Directly To Discuss Their Options NEW YORK ...